Roivant’s JAK/TYK2 inhibitor fails PhII lupus study

Roivant re­port­ed Mon­day morn­ing that a pro­gram li­censed from Pfiz­er failed a Phase II lu­pus tri­al and that it would end de­vel­op­ment in the con­di­tion.

The drug, known as bre­poc­i­tinib, did not achieve sta­tis­ti­cal sig­nif­i­cance in a study com­par­ing it to place­bo in adults with mod­er­ate to se­vere ac­tive lu­pus. Roivant and the “Vant” hous­ing the drug, Pri­o­vant, blamed a high place­bo rate for the flop.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.